MA47450A - Sulfinylpyridines et leur utilisation dans le traitement du cancer - Google Patents
Sulfinylpyridines et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA47450A MA47450A MA047450A MA47450A MA47450A MA 47450 A MA47450 A MA 47450A MA 047450 A MA047450 A MA 047450A MA 47450 A MA47450 A MA 47450A MA 47450 A MA47450 A MA 47450A
- Authority
- MA
- Morocco
- Prior art keywords
- sulfinylpyridines
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455645P | 2017-02-07 | 2017-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47450A true MA47450A (fr) | 2019-12-18 |
Family
ID=61226605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047450A MA47450A (fr) | 2017-02-07 | 2018-02-07 | Sulfinylpyridines et leur utilisation dans le traitement du cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11208384B2 (enExample) |
| EP (1) | EP3580204A1 (enExample) |
| JP (1) | JP2020507624A (enExample) |
| KR (1) | KR20190115011A (enExample) |
| CN (1) | CN110382465A (enExample) |
| AU (1) | AU2018218518B2 (enExample) |
| BR (1) | BR112019016258A2 (enExample) |
| CA (1) | CA3051644A1 (enExample) |
| MA (1) | MA47450A (enExample) |
| MX (1) | MX2019009356A (enExample) |
| RU (1) | RU2019127896A (enExample) |
| WO (1) | WO2018146468A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| CA3051644A1 (en) * | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| MX389800B (es) | 2017-02-07 | 2025-03-20 | Oblique Therapeutics Ab | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer |
| US20210038577A1 (en) * | 2018-02-12 | 2021-02-11 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE4643T1 (de) | 1979-12-19 | 1983-09-15 | Duphar International Research B.V | Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen. |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) * | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| JP2002515023A (ja) | 1995-08-24 | 2002-05-21 | ビーエーエスエフ アクチェンゲゼルシャフト | Ｎ−複素環化合物、その製造用中間体、それを含む組成物及び有害菌類防除にそれを使用する方法 |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| JP2001519345A (ja) | 1997-10-02 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| DK0930302T3 (da) | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| US20060019967A1 (en) * | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| US20100048713A1 (en) | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| CA2647338A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| WO2007137255A2 (en) * | 2006-05-22 | 2007-11-29 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| EP2435040A2 (en) * | 2009-05-28 | 2012-04-04 | President and Fellows of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| EP2535059A4 (en) | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF) |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| EP2811990B1 (en) | 2012-02-10 | 2017-10-25 | The Board of Regents of The University of Texas System | Modulators of exchange proteins directly activated by camp (epacs) |
| US8946418B1 (en) | 2013-07-10 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
| MX389800B (es) | 2017-02-07 | 2025-03-20 | Oblique Therapeutics Ab | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer |
| CA3051644A1 (en) * | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
-
2018
- 2018-02-07 CA CA3051644A patent/CA3051644A1/en active Pending
- 2018-02-07 WO PCT/GB2018/050342 patent/WO2018146468A1/en not_active Ceased
- 2018-02-07 MX MX2019009356A patent/MX2019009356A/es unknown
- 2018-02-07 MA MA047450A patent/MA47450A/fr unknown
- 2018-02-07 US US16/484,074 patent/US11208384B2/en not_active Expired - Fee Related
- 2018-02-07 BR BR112019016258A patent/BR112019016258A2/pt not_active IP Right Cessation
- 2018-02-07 KR KR1020197024689A patent/KR20190115011A/ko not_active Ceased
- 2018-02-07 EP EP18705460.6A patent/EP3580204A1/en not_active Withdrawn
- 2018-02-07 CN CN201880010215.8A patent/CN110382465A/zh active Pending
- 2018-02-07 AU AU2018218518A patent/AU2018218518B2/en not_active Ceased
- 2018-02-07 JP JP2019563696A patent/JP2020507624A/ja active Pending
- 2018-02-07 RU RU2019127896A patent/RU2019127896A/ru unknown
-
2021
- 2021-12-15 US US17/551,925 patent/US20220177430A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11208384B2 (en) | 2021-12-28 |
| CN110382465A (zh) | 2019-10-25 |
| EP3580204A1 (en) | 2019-12-18 |
| KR20190115011A (ko) | 2019-10-10 |
| AU2018218518B2 (en) | 2022-03-17 |
| US20220177430A1 (en) | 2022-06-09 |
| RU2019127896A (ru) | 2021-03-09 |
| RU2019127896A3 (enExample) | 2021-05-18 |
| CA3051644A1 (en) | 2018-08-16 |
| AU2018218518A1 (en) | 2019-08-15 |
| MX2019009356A (es) | 2019-09-19 |
| BR112019016258A2 (pt) | 2020-04-07 |
| WO2018146468A1 (en) | 2018-08-16 |
| JP2020507624A (ja) | 2020-03-12 |
| US20200024233A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
| EP3684353A4 (en) | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| EP3796920A4 (en) | TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER | |
| EP3673947A4 (en) | CATHETER AND CATHETER KIT | |
| MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
| EP2969010A4 (en) | USE OF LEVOCETIRIZIN AND MONTELUCASTIC FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA47458A (fr) | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| EP2969002A4 (en) | USE OF LEVOCETIRIZIN AND MONTELUCASTIC FOR THE TREATMENT OF TRAUMATIC INJURIES | |
| EP3678692A4 (en) | GENOTYPE STRATIFICATION IN THE TREATMENT AND PREVENTION OF DIABETES | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| EP3258964A4 (en) | IDENTIFICATION AND TREATMENT OF MALIGNEN TUMORS IN THE CNS | |
| EP3349742A4 (en) | USE OF NICLOSAMIDE IN THE TREATMENT OF P53 DEFICIENT CELLS | |
| EP3397063A4 (en) | USE OF MICRO AND NANOBLAS IN LIQUID PROCESSING | |
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
| EP3363461A4 (en) | ANTI-CD43 ANTIBODIES AND USE THEREOF FOR CANCER TREATMENT |